Aptevo Therapeutics INC 8-K filings

Aptevo Therapeutics announced second-quarter 2026 financial results and a business update, detailing strong clinical momentum for mipletamig in AML, a new Chief Scientific Officer, non-dilutive funding for APVO451, and a radiopharmaceutical collaboration with Niowave.

Aptevo Therapeutics announced the closing of a transaction involving the exercise of existing warrants and a private placement, raising approximately $4.5 million in gross proceeds.

Aptevo Therapeutics announced a new solid tumor strategy and filed a patent for a Nectin-4 x PD-L1 dual-targeting backbone to enhance its oncology pipeline and expand partnering opportunities.

Aptevo Therapeutics has been awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to advance its trispecific antibody candidate, APVO451, for solid tumors.

Aptevo Therapeutics and Niowave have entered into a 50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs, with Niowave making a strategic equity investment in Aptevo.

Aptevo Therapeutics announced its first-quarter 2026 business update, highlighting strong clinical data for mipletamig in frontline AML and a completed executive leadership transition.

Aptevo Therapeutics announced a leadership transition with Marvin L. White moving to Executive Chair and Jeff Lamothe becoming President and CEO, effective April 1, 2026.

Aptevo Therapeutics has entered into a $60 million equity line of credit with Yorkville Advisors Global, LP, extending its funding runway into 2029 to advance its multispecific portfolio.

Aptevo Therapeutics Inc. has completed a 1-for-18 reverse stock split, effective December 29, 2025, to consolidate its common stock.

Aptevo Therapeutics announced compelling safety and high remission rates for its drug candidate mipletamig in frontline acute myeloid leukemia patients at ASH 2025.

Aptevo Therapeutics announced positive mipletamig trial results for AML, introduced new trispecific candidates, and extended its cash runway into late 2026.

Aptevo Therapeutics Inc. announced an amendment to its Rights Agreement, extending the expiration date of its shareholder rights plan to October 29, 2026.

Aptevo Therapeutics announced a 100% remission rate in Cohort 3 of its RAINIER trial for newly diagnosed AML patients unfit for intensive chemotherapy, with no dose-limiting toxicities.

Aptevo Therapeutics announced the filing of two provisional patents for novel trispecific anti-cancer candidates, APVO452 and APVO451, targeting prostate and various solid tumor types.

Aptevo Therapeutics announced positive second-quarter 2025 financial results and a significant expansion of its bispecific T-cell engager pipeline, highlighted by an 85% remission rate for mipletamig in frontline AML.

Aptevo Therapeutics Inc. stockholders approved all eight proposals at the 2025 Annual Meeting, including a reverse stock split, significant dilutive equity issuances, and executive compensation.

Aptevo Therapeutics Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement after successfully raising approximately $15.9 million in additional equity capital.

Aptevo Therapeutics Inc. has announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement by raising approximately $15.9 million through a series of equity offerings.

Aptevo Therapeutics Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, effective June 23, 2025, following the merger of its previous auditor, Moss Adams LLP, with Baker Tilly, though prior audit reports included a going concern uncertainty.

Aptevo Therapeutics Inc. has filed a prospectus supplement to update its existing At The Market (ATM) offering program, allowing for the sale of up to an additional $8,037,381 in common stock.

Aptevo Therapeutics Inc. has successfully closed an $8 million public offering to fund clinical programs and general corporate purposes, while also announcing compelling clinical data for its lead AML therapeutic, mipletamig, and expanding its CD3-directed oncology pipeline.

Aptevo Therapeutics Inc. has entered into a Standby Equity Purchase Agreement with Yorkville for up to $25 million in common stock, providing flexible access to capital over 36 months.

Aptevo Therapeutics Inc. has announced a 1-for-20 reverse stock split of its common stock, effective May 23, 2025, aimed at increasing its per share price to meet Nasdaq listing requirements.

Aptevo Therapeutics received a Nasdaq notification regarding non-compliance with minimum stockholders' equity requirements and is implementing a reverse stock split while also offering shares under an existing agreement.

Aptevo Therapeutics announces first quarter 2025 financial results and provides a positive update on its mipletamig clinical trial for acute myeloid leukemia (AML), highlighting strong remission rates and a favorable safety profile.

Aptevo Therapeutics has filed a prospectus supplement with the SEC to offer and sell up to $3.17 million of its common stock under an existing 'at-the-market' offering agreement.

Aptevo Therapeutics enters into an agreement with Roth Capital Partners to sell up to $2,959,952 of common stock through an at-the-market offering.

Aptevo Therapeutics has successfully completed a registered direct offering, raising $2.0 million to advance its clinical programs and for general corporate purposes.

Aptevo Therapeutics successfully closes a $2.1 million registered direct offering and concurrent private placement to fund clinical development and working capital.

Aptevo Therapeutics reports that two additional patients in the RAINIER trial achieved remission within 30 days of treatment with mipletamig in combination with standard of care for frontline AML.